Mobile

An open-label, non-randomized, sequential, multicenter study to evaluate the pharmacokinetics, efficacy and safety of once daily dosing compared to twice daily dosing of Orfadin in patients diagnosed ...

Mise à jour : Il y a 5 ans
Référence : EUCTR2013-004132-29

An open-label, non-randomized, sequential, multicenter study to evaluate the pharmacokinetics, efficacy and safety of once daily dosing compared to twice daily dosing of Orfadin in patients diagnosed with hereditary tyrosinemia type 1

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the steady-state exposure to nitisinone during once and twice daily dosing of Orfadin

Critère d'inclusion

  • hereditary tyrosinemia type 1

Liens